Kelly M. Reitmeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelly M. Reitmeyer has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Abdul Azim
Rutgers Robert Wood Johnson Medical School
1 shared publication - Arsheena Yassin
Robert Wood Johnson University Hospital
1 shared publication Brijesh Rana
Rutgers University School of Public Health, Piscataway, NJ, USA
1 shared publication- David Awad
Department of Pharmacy, Robert Wood Johnson University Hospital, New Brunswick, NJ, USA
1 shared publication Esther Huang
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
1 shared publication- Jiyeon Joy Park
Department of Pharmacy, Englewood Health, Englewood, NJ, USA
1 shared publication
Latest Publications
- Open Access
- 5 August 2024
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 4 (1) , e107
Effectiveness of oral vancomycin as prophylaxis against Clostridioides difficile infection in hematopoietic stem cell transplant patients
Objective: Patients receiving hematopoietic stem cell transplants (HSCT) are at increased risk for Clostridioides difficile infection (CDI). The purpose of this study was to assess the effectiveness of oral vancomycin prophylaxis (OVP) for CDI in HSCT patients. Design: Single-center, retrospective cohort. Setting: Tertiary care academic medical center in New Jersey. Patients: Patients ≥18 years old during admission for the HSCT were included. Patients who were admitted P = .0147). There were no significant (P > .05) between-group differences in incidence of gram-negative bloodstream infections, hospital survival, and length of stay. There were zero clinical cultures positive for VRE. Conclusions: In-hospital incidence of CDI in HSCT patients was significantly decreased with OVP. Randomized controlled trials are needed in this high-risk population to assess the efficacy and risks of OVP for CDI.
- 5 August 2024
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 4 (1) , e107
Open AccessEffectiveness of oral vancomycin as prophylaxis against Clostridioides difficile infection in hematopoietic stem cell transplant patients
Objective: Patients receiving hematopoietic stem cell transplants (HSCT) are at increased risk for Clostridioides difficile infection (CDI). The purpose of this study was to assess the effectiveness of oral vancomycin prophylaxis (OVP) for CDI in HSCT patients. Design: Single-center, retrospective cohort. Setting: Tertiary care academic medical center in New Jersey. Patients: Patients ≥18 years old during admission for the HSCT were included. Patients who were admitted P = .0147). There were no significant (P > .05) between-group differences in incidence of gram-negative bloodstream infections, hospital survival, and length of stay. There were zero clinical cultures positive for VRE. Conclusions: In-hospital incidence of CDI in HSCT patients was significantly decreased with OVP. Randomized controlled trials are needed in this high-risk population to assess the efficacy and risks of OVP for CDI.